Related Experiment Video
Updated: Feb 25, 2026
11:31
High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
8.5K
Tolerogenic Nanoparticles to Treat Islet Autoimmunity
Tobias Neef1, Stephen D Miller2
1Department of Microbiology-Immunology and Interdepartmental Immunobiology Center, Feinberg School of Medicine, Northwestern University, 6-713 Tarry Building, 303 E. Chicago Avenue, Chicago, IL, 60611, USA.
Current Diabetes Reports
|August 10, 2017
Summary
Tolerogenic nanoparticles show promise for treating type 1 diabetes (T1D) by mitigating autoimmune attacks on islets. Research is advancing, focusing on translating these nanomedicine strategies from preclinical models to human therapies.
Area of Science:
- Immunology
- Nanomedicine
- Endocrinology
Background:
- Type 1 diabetes (T1D) is currently managed with insulin replacement therapy.
- Broad immunosuppression for autoimmune diseases has significant drawbacks.
- Antigen-specific tolerance induction is a preferred therapeutic strategy for T1D.
Purpose of the Study:
- To review nanomedicine applications for T1D treatment.
- To highlight strategies for developing tolerogenic nanoparticles.
- To mitigate islet-destroying autoimmunity in T1D.
Main Methods:
- Review of current research on tolerogenic nanoparticles for T1D.
- Analysis of nanotechnology applications in T1D treatment, including islet transplantation and encapsulation.
- Exploration of diverse nanoparticle-based tolerance induction strategies.
Main Results:
- Progress is being made in applying tolerogenic nanoparticles in rodent models of T1D.
- Nanotechnology supports other T1D treatment modalities like islet transplantation.
- Various strategies are being employed for nanoparticle-mediated tolerance induction.
Conclusions:
- Nanomedicine offers a promising avenue for T1D treatment through tolerogenic nanoparticles.
- Future research will likely involve more diverse tolerance induction strategies.
- Translating nanoparticle technology from preclinical studies to human T1D treatment is a key focus.
